Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242706 (
hyperoxia
)
5,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Xanthine oxidoreductase
(
XOR
) catalyzes the final reactions of purine catabolism and may account for cell damage by producing reactive oxygen metabolites in cells reoxygenated after hypoxia. We found a three- to eightfold higher
XOR
activity in cultured human bronchial epithelial cells exposed to hypoxia (0.5-3% O2) compared with cells grown in normoxia (21% O2) but no difference in
XOR
protein or mRNA.
XOR
promoter constructs failed to respond to hypoxia. The cellular
XOR
activity at 3% O2 returned to basal levels when the cells were returned to 21% O2, and
hyperoxia
(95% O2) abolished enzyme activity with no change in
XOR
protein. Our data suggest reversible enzyme inactivation by oxygen or its metabolites. NADH was normally oxidized by the oxygen-inactivated enzyme, which rules out damage to the flavin adenine dinucleotide cofactor. Hydrogen peroxide partially inactivated the molybdenum center of
XOR
, as shown by a parallel decrease in
XOR
-catalyzed xanthine oxidation and dichlorophenolindophenol reduction. We conclude that the transcription or translation of
XOR
is not influenced by hypoxia or
hyperoxia
. Instead, the molybdenum center of
XOR
is posttranslationally inactivated by oxygen metabolites in "normal" (21% O2) cell culture atmosphere. This inactivation is reversed in hypoxia and accounts for the apparent induction.
...
PMID:Posttranslational inactivation of human xanthine oxidoreductase by oxygen under standard cell culture conditions. 1263 68